Association between PIK3CA alteration and prognosis of gastric cancer patients: a meta-analysis

Li, Hua; Chen, Shubo; Li, Hui; Cui, Jianxin; Gao, Yunhe; Wu, Dianchao; Luan, S.; Yan, Qin; Zhai, Tongshan; Liu, Dengxiang; Huo, Zhibin

doi:10.18632/oncotarget.23871

Cited by 8 publications

(4 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results showed that PIK3CA mutations were positively associated with T category, N category, stage, perineural invasion, and venous invasion. Consistent with other studies of GC (14,15,22,24,25), the current data also showed no association between PIK3CA mutation and prognosis. However, a novel finding in this study was that patients with exon 9 PIK3CA mutation exhibited lower DFS and OS rates than those without exon 9 PIK3CA mutation, although no independent correlation was demonstrated.…”

Section: Discussionsupporting

confidence: 92%

“…Another study also confirmed no relationship between PIK3CA mutations and clinical outcomes (13). However, in a recent meta-analysis of 2, 481 patients in 11 trials using pooled estimates for OS, Li et al evaluated the relationship between PIK3CA expression and GC prognosis and found no correlation between PIK3CA gene mutation and OS, yet significant association with poor tumor differentiation (14). In the case of EBV-GC, Böger et al reported that the PIK3CA status had no significant effect on OS or tumor-specific survival, suggesting an intratumoral heterogeneity of PIK3CA mutations (15).…”

mentioning

confidence: 96%

See 1 more Smart Citation

Exon 9 Mutation of PIK3CA Associated With Poor Survival in Patients With Epstein-Barr Virus-associated Gastric Cancer

et al. 2019

View full text Add to dashboard Cite

Background: Epstein-Barr virus (EBV)-associated gastric cancer (GC) is known to harbor a significant enrichment of of phosphatidylinositol 4, 5-biphosphate 3-kinase catalytic subunit alpha isoform (PIK3CA). Therefore, this study investigated the clinical relevance and prognostic role of PIK3CA mutations in patients with EBV-GC. Materials and Methods: After reviewing 1,318 consecutive cases of surgically resected GC, 120 patients were identified as EBV-positive using EBV-encoded RNA in situ hybridization. PIK3CA mutations were identified in formalin-fixed and paraffin-embedded surgical specimens from 112 patients with EBV-GC with available tumor tissue samples. Real-time polymerase chain reaction was used to evaluate hot-spot mutations of exons 1, 4, 7, 9, and 20 of PIK3CA. Results: Among the 112 patients, the frequency of PIK3CA mutations was 25.0% (n=28), and among the 28 patients harboring a PIK3CA mutation, most mutations were identified in exon 9 (n=21, 18.8%). The presence of PIK3CA mutation was also correlated with a higher T category (p<0.001) and N category (p<0.001), as well as the presence of perinueral invasion (p<0.001) and venous invasion (p<0.001). In a univariate analysis, PIK3CA mutation showed no association with overall survival (OS) (p=0.184) or disease-free survival (DFS) (p=0.150). Patients harboring exon 9 PIK3CA mutations exhibited a significantly shorter OS (p=0.023) and DFS (p=0.013) than the patients lacking an exon 9 PIK3CA mutation, yet without statistical significance in the multivariate analysis. Notably, exon 9 E542K mutation of PIK3CA was associated with the worst DFS (p=0.011). Conclusion: The current data show that PIK3CA mutations appear to play an important role in carcinogenesis and tumor aggressiveness in EBV-GC, and also support the concept that exon 9 mutation of PIK3CA is a prognostic indicator for predicting patient outcomes and a rationale for therapeutic targeting in EBV-GC.The Cancer Genome Atlas (TCGA) research group identified four genomic subtypes of gastric cancer (GC): Epstein-Barr 2145

show abstract

Section: Discussionsupporting

confidence: 92%

mentioning

confidence: 96%

Exon 9 Mutation of PIK3CA Associated With Poor Survival in Patients With Epstein-Barr Virus-associated Gastric Cancer

et al. 2019

View full text Add to dashboard Cite

show abstract

“…This has signi cance for the treatment of patients. A meta-analysis by Hua et al showed that PIK3CA mutations are indicators of poorly differentiated tumors [12]. These results are consistent with the immunohistochemical results.…”

Section: Discussionsupporting

confidence: 68%

Two cases of gastrointestinal tumor with uterine cervical metastases: a case report

Xie

Zhang

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: Gastrointestinal (GI) tumors are among the most prevalent malignant tumors worldwide. Recurrence and metastasis remain the leading causes of advanced GI tumor-related mortality. We present two rare cases of uterine cervical metastases from GI tumors and describe the clinical and pathological diagnosis, therapeutic options, and prognosis from a molecular biology perspective. Case presentation: We present the case of a 55-year-old Asian woman treated for sigmoid adenocarcinoma. The patient underwent a sigmoid colon resection without chemotherapy. Six months later, the tumor in the patient’s pelvis recurred, and she underwent pelvic lesion resection and bilateral adnexectomy. The patient underwent frequent chemotherapy, radiotherapy, targeted therapy, and immunotherapy after surgery. Five years later, the patient was diagnosed with intestinal cancer and cervical metastasis due to vaginal bleeding. Another case involved a 54-year-old Asian woman with poorly differentiated adenocarcinoma of the stomach who underwent radical gastrectomy, left adnexal metastasis 1 year later, and bilateral adnexectomy. After surgery, insufficient chemotherapy was administered, and a year later, vaginal bleeding revealed metastatic adenocarcinoma of the cervix. Conclusions: Although cervical metastases from gastrointestinal tumors are rare, physicians should be aware of this risk. According to these guidelines, surgical resection is necessary for isolated cervical metastases, and systemic treatment is preferred if multiple metastases are present. However, in the present case, surgery was performed despite multiple metastases, which prolonged the patient's survival and improved the quality of life. Treatment options should be individualized. It has been suggested that such patients undergo genetic testing to facilitate targeted drug selection and improve treatment outcomes.

show abstract

“…Wu et al showed that PI3K/AKT/mTOR activation induced by PIK3CA upregulation promotes GC progression and chemoresistance [ 23 ]. A meta-analysis showed that high PIK3CA expression is closely related to poor prognosis in patients with gastric cancer [ 24 ]. Therefore, targeting PIK3CA is an effective strategy for increasing the survival time of patients with GC.…”

Section: Discussionmentioning

confidence: 99%

Network pharmacology, molecular docking and experimental verification help unravel chelerythrine's potential mechanism in the treatment of gastric cancer

Kai,

Han-bing,

Bing-lin

et al. 2023

Heliyon

View full text Add to dashboard Cite

Association between PIK3CA alteration and prognosis of gastric cancer patients: a meta-analysis

Cited by 8 publications

References 33 publications

Exon 9 Mutation of PIK3CA Associated With Poor Survival in Patients With Epstein-Barr Virus-associated Gastric Cancer

Exon 9 Mutation of PIK3CA Associated With Poor Survival in Patients With Epstein-Barr Virus-associated Gastric Cancer

Two cases of gastrointestinal tumor with uterine cervical metastases: a case report

Network pharmacology, molecular docking and experimental verification help unravel chelerythrine's potential mechanism in the treatment of gastric cancer

Contact Info

Product

Resources

About